The workforce reduction is expected to save the drugmaker $10 million in 2018. After the job cuts, the company will have approximately 70 employees.
“While it is difficult to undertake a restructuring, we believe through efficient use of our capital, we will have the potential to build significant value in our Factor D inhibitor portfolio,” said Achillion CEO Milind Deshpande, PhD.
In the fiscal year ended Dec. 31, 2017, the company reported an $85.2 million net loss, compared to $61.7 million in fiscal year 2016. In addition, the company reported a fourth quarter net loss of $23.2 million, compared to a net loss of $4.4 million the same period a year prior.
The drugmaker’s research and development expenses also increased in fiscal year 2017, rising to $65.1 million in comparison to the year prior, which had $59.2 million in research and development expenses.
Achillion attributes the increase in expenses to clinical trial costs for its lead drug, ACH-4471.
More articles on supply chain:
Amazon quietly launches exclusive OTC product line: 7 things to know
Roche’s diabetes app recalled over software bug: 4 things to know
Pharma deals in an era of heightened competition: 6 recent drugmaker transactions, partnerships
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
